×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Drugs and Devices

Although overuse of antibiotics gets most of the attention, many people in low-and middle-income countries die because they lack access to antibiotics, according to a report from the Center for Disease Dynamics, Economics & Policy.

Read more at The Center for Disease Dynamics, Economics & Policy . . .

On March 26, the FDA approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Read more at FDA.gov . . .

On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program that requires the drug be administered by a healthcare provider in a certified health care facility.

Read more at FDA.gov . . .

Having a family member with persistent opioid use may be a risk factor for young adults (aged 13 to 21 years) continuing prescriptions long after their own surgeries, according to a study in JAMA Surgery.

Read more via Michigan Medicine Health Lab . . .

On Feb. 14, the FDA approved Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2). This new type of insulin pump, referred to as an alternate controller enabled (ACE) infusion pump, or ACE insulin pump, is the first interoperable pump, meaning it can be . . .

According to a Feb. 11 statement by the FDA, about 4.9 million middle and high school students had used were current users (used in the past 30 days) of some type of tobacco product in 2018, up from 3.6 million in 2017. A surge in e-cigarette use . . .

On Feb. 6, the FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Read more via U.S. Food & Drug Administration . . .

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing